Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease 007

PHASE3CompletedINTERVENTIONAL
Enrollment

428

Participants

Timeline

Start Date

July 31, 2002

Primary Completion Date

October 31, 2003

Study Completion Date

October 31, 2003

Conditions
Coronary Artery Disease
Interventions
DRUG

PB127 for injectable suspension

0.175 mg/kg diluted in 150 mL Dextrose in Water 5% in glass bottles to be infused at 250 mL/hour until stead state achieve, 150 mL/hour during rest image acquisition, and 100-150 mL/hr during stress image acquistion. Single IV infusion, not to exceed 60 minutes.

Trial Locations (19)

10025

St. Luke's Roosevelt Hospital Echocardiography Lab, New York

10029

Mount Sinai Hospital, New York

22908

University of Virginia Health System, Charlottesville

43214

MidWest Cardiologist Research, Columbus

46202

Krannert Institute of Cardiology, Indianapolis

63110

Washington University School of Medicine, St Louis

64111

Cardiovascular Consultants, Kansas City

66204

The Center for Cardiovascular Studies Kramer & Crouse Cardiology, Shawnee Mission

75231

Presbyterian Hospital of Dallas, Dallas

77030

Methodist DeBakery Heart Center Cardiovascular Imaging Institute, Houston

78705

Austin Heart, Austin

85258

Heartcare, P.C., Scottsdale

85259

Mayo Clinic Scottsdale, Scottsdale

94143

University of California San Francisco, San Francisco

94305

Stanford University Medical Center, Stanford

97401

Endovascular Research, LLC, Eugene

99204

Inland Cardiology, Spokane

04210

Androscoggin Cardiovascular Associates, Auburn

04106

Maine Cardiology Associates, South Portland

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Point Biomedical

INDUSTRY